DEFA1: A Potential Drug Target and Biomarker (G1667)

Target Name: DEFA1

NCBI ID: G1667

DEFA1

DEFA1: A Potential Drug Target and Biomarker

DEFA1 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a heat-labile protein that consists of 158 amino acids and has a calculated pI of 11.6. DEFA1 is involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in the development and progression of various diseases, including cancer.

The search for potential drug targets and biomarkers is a crucial aspect of modern medicine. Drug targets are proteins that are associated with a specific disease or disorder and are targeted by drugs to inhibit their activity. Biomarkers are proteins that are produced by the body that can be used as indicators of a specific disease or disorder.

DEFA1 is a potential drug target because of its involvement in the regulation of cellular processes and its association with various diseases. Its function in cell adhesion, migration, and invasion makes it a potential target for drugs that can modulate these processes. DEFA1 has also been shown to be involved in the development and progression of cancer, which makes it an attractive target for drugs that can inhibit its activity.

In addition to its potential as a drug target, DEFA1 is also a potential biomarker. Its expression has been shown to be elevated in various tissues and has been used as a biomarker for various diseases, including cancer. Its heat-labile nature makes it a potential protein biomarker for cancer, as heat-labile proteins are more likely to be expressed and can be used as biomarkers in cancer.

One approach to identifying potential drug targets and biomarkers is to use a screening approach, such as high-throughput screening assays. These assays involve the use of antibodies to target specific proteins and measure their activity or expression levels. By using these assays, researchers can identify potential drug targets and biomarkers that are involved in the regulation of cellular processes or that are associated with various diseases.

Another approach to identifying potential drug targets and biomarkers is to use bioinformatics tools to predict the potential targets and biomarkers of a protein. These tools can analyze the protein's sequence and structure to identify potential binding sites and predict the potential functions of the protein. By using these tools, researchers can identify potential drug targets and biomarkers that are involved in the regulation of cellular processes or that are associated with various diseases.

Once potential drug targets and biomarkers have been identified, they can be further characterized to determine their effectiveness and safety. This involves a process called drug discovery, which involves the development of compounds that can interact with the potential drug targets and biomarkers. These compounds are then tested for their ability to inhibit the activity of the target or to detect the presence of the biomarker.

Once a potential drug or biomarker has been identified and its activity has been characterized, it can be tested in clinical trials to determine its effectiveness and safety. Clinical trials involve the use of controlled studies to evaluate the safety and effectiveness of the drug or biomarker in humans. These studies are conducted in three phases: Phase 1, Phase 2, and Phase 3.

Phase 1 involves the testing of the safety of the drug or biomarker in healthy volunteers. This involves the administration of the drug or biomarker to a group of volunteers and the measurement of any adverse effects that occur.

Phase 2 involves the testing of the safety and effectiveness of the drug or biomarker in patients with the targeted disease. This involves the administration of the drug or biomarker to patients and the measurement of any

Protein Name: Defensin Alpha 1

Functions: Effector molecule of the innate immune system that acts via antibiotic-like properties against a broad array of infectious agents including bacteria, fungi, and viruses or by promoting the activation and maturation of some APCs (PubMed:15616305, PubMed:17142766, PubMed:20220136, PubMed:24236072). Interacts with the essential precursor of cell wall synthesis lipid II to inhibit bacterial cell wall synthesis (PubMed:20214904). Inhibits adenovirus infection via inhibition of viral disassembly at the vertex region, thereby restricting the release of internal capsid protein pVI, which is required for endosomal membrane penetration during cell entry (PubMed:18191790). In addition, interaction with adenovirus capsid leads to the redirection of viral particles to TLR4 thereby promoting a NLRP3-mediated inflammasome response and interleukin 1-beta (IL-1beta) release (PubMed:35080426). Induces the production of proinflammatory cytokines including type I interferon (IFN) in plasmacytoid dendritic cells (pDCs) by triggering the degradation of NFKBIA and nuclear translocation of IRF1, both of which are required for activation of pDCs (PubMed:27031443)

The "DEFA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets